Medpace (NASDAQ:MEDP) and HedgePath Pharmaceuticals (OTCMKTS:HPPI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Medpace and HedgePath Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medpace 0 1 3 0 2.75
HedgePath Pharmaceuticals 0 0 0 0 N/A

Medpace currently has a consensus target price of $74.67, suggesting a potential downside of 4.31%. Given Medpace’s higher probable upside, research analysts clearly believe Medpace is more favorable than HedgePath Pharmaceuticals.

Profitability

This table compares Medpace and HedgePath Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Medpace 11.28% 17.65% 10.88%
HedgePath Pharmaceuticals N/A N/A -306.77%

Earnings & Valuation

This table compares Medpace and HedgePath Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medpace $704.59 million 3.98 $73.18 million $2.59 30.13
HedgePath Pharmaceuticals N/A N/A -$4.55 million N/A N/A

Medpace has higher revenue and earnings than HedgePath Pharmaceuticals.

Volatility and Risk

Medpace has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, HedgePath Pharmaceuticals has a beta of -1.16, indicating that its stock price is 216% less volatile than the S&P 500.

Insider & Institutional Ownership

77.0% of Medpace shares are held by institutional investors. 24.2% of Medpace shares are held by insiders. Comparatively, 4.8% of HedgePath Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Medpace beats HedgePath Pharmaceuticals on 10 of the 10 factors compared between the two stocks.

About Medpace

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.

About HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.